RCP Therapeutics, a biopharmaceuticals company, has announced that it has exclusively licensed technologies from Telemolecular Corporation (US).
New management, appointed to run Telomolecular Corporation in May 2008, set in motion a business strategy culminating in the formation of RCP Therapeutics and this announcement.
Operationally, Telomolecular will retain its research laboratory in Sacramento, securing the facilities status as the primary research and development site of RCP Therapeutics.
RCP plans to expand the Californian operation and increase the number of scientists and staff employed at the site.
Commercialisation of RCP's cosmeceutical products in the US will be co-ordinated from the same location.
'Our vision for Telomolecular is focused on the convergence between nanotechnologies and cellular targeting,' said Robert Sexauer, chief executive officer of RCP Therapeutics.
